High-definition transcranial direct current stimulation helps treat pain in fibromyalgia patients

NewsGuard 100/100 Score

Imagine significantly reducing a persistent migraine or fibromyalgia by a visit to a doctor who delivers low doses of electricity to the brain.

Alex DaSilva, assistant professor of prosthodontics at the University of Michigan, and colleagues are optimizing the next generation for such a technique, called high-definition transcranial direct current stimulation, or HD-tDCS.

The researchers have published several studies with the conventional tDCS, which also treats pain by "shocking" the brain with low doses of electrical current delivered noninvasively through electrodes placed on the scalp. The current modulates targeted areas of the brain, and one of the mechanisms is by activating the release of opioid-like painkillers.

HD-tDCS delivers an even more precisely focused current to the targeted areas of the brain. Preliminary reports have shown better pain relief in patients and a longer and more pronounced effect on the brain, said DaSilva, who heads the Headache and Orofacial Pain Effort Laboratory at the U-M School of Dentistry.

The increased precision of HD-tDCS means researchers can custom-place the electrodes to the skull. In this way, they can modulate specific areas in the brain to treat a wider range of conditions, such as neuropathic pain and stroke. Other uses include neurophysiological studies and cognitive and behavioral assessments.

One 20-minute session of HD-tDCS significantly reduced overall pain perception in fibromyalgia patients as described in one of the studies.

Researchers control the current by a portable device, which they hope physicians can eventually use in the clinic as a noninvasive treatment for chronic pain patients.

"We are working hard to make the technology available for clinical use at U-M," DaSilva said. "Our lab is getting a good number of emails from chronic pain patients looking for treatment."

The conventional technology is already available for many companies, and the HD-tDCS is being patented by the company of one of the developers.

Comments

  1. James Fugedy James Fugedy United States says:

    Precision of targeting is only one factor influencing the clinical effects of tDCS. Equally or more important are effects on tracts and areas of the brain distant from the stimulation site. A 2 electrode montage may produce less specific but more robust clinical responses.

    Although the most effective protocols are probably yet to be developed. Current protocols already demonstrate clinical benefit. For example, a 2 electrode montage using a 20-minute daily treatment for 5 days was shown to reduce fibromyalgia pain by 50% 7 years ago.

    Select clinics provide tDCS therapy for conditions which respond, including fibromyalgia, migraine, CRPS and treatment-resistant uni- and bi-polar depression. There is also an option for home-use for appropriate patients. The fact that tDCS has no side effects and is easy to do permits at-home use.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research finds link between unhealthy eating and chronic pain severity, calls for comprehensive dietary support